TG Therapeutics Investigational Trial Site

Knoxville, Tennessee 37996

2 studies enrolling now · 7 studies all time

What they study most

Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Multiple Sclerosis, Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis, Small Lymphocytic Lymphoma

Studies at this site

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — Recruiting now
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — Recruiting now
• An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis — Running, not enrolling
• Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) — Stopped early
• An Extension of the TG1101-RMS201 Trial — Completed
• Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma — Stopped early
• Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis — Completed